Investigational Drug Information for Sulopenem
✉ Email this page to a colleague
What is the development status for investigational drug Sulopenem?
Sulopenem is an investigational drug.
There have been 7 clinical trials for Sulopenem.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 18th 2018.
The most common disease conditions in clinical trials are Communicable Diseases, Infections, and Infection. The leading clinical trial sponsors are Iterum Therapeutics, International Limited, Iterum Therapeutics, US Limited, and Pfizer.
There are one hundred and thirty-two US patents protecting this investigational drug and seven hundred and thirty-four international patents.
Summary for Sulopenem
US Patents | 132 |
International Patents | 734 |
US Patent Applications | 287 |
WIPO Patent Applications | 185 |
Japanese Patent Applications | 47 |
Clinical Trial Progress | Phase 3 (2018-09-18) |
Vendors | 20 |
Recent Clinical Trials for Sulopenem
Title | Sponsor | Phase |
---|---|---|
Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women | Iterum Therapeutics, International Limited | Phase 3 |
Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents | Iterum Therapeutics, International Limited | Phase 1 |
Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults | Iterum Therapeutics, International Limited | Phase 3 |
Clinical Trial Summary for Sulopenem
Top disease conditions for Sulopenem
Top clinical trial sponsors for Sulopenem
US Patents for Sulopenem
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Sulopenem | ⤷ Sign Up | Methods of treating inflammation associated airway diseases and viral infections | WASHINGTON STATE UNIVERSITY (Pullman, WA) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX) | ⤷ Sign Up |
Sulopenem | ⤷ Sign Up | Use of gelsolin to treat infections | The Brigham and Women's Hospital, Inc. (Boston, MA) | ⤷ Sign Up |
Sulopenem | ⤷ Sign Up | Compositions and methods for delivering an agent to a wound | UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION (Memphis, TN) | ⤷ Sign Up |
Sulopenem | ⤷ Sign Up | Oral appliance for delivering a medicament | ⤷ Sign Up | |
Sulopenem | ⤷ Sign Up | Method for using novel hydroxamic acid derivative and antibacterial substance in combination | TOYAMA CHEMICAL CO., LTD. (Shinjuku-ku, JP) | ⤷ Sign Up |
Sulopenem | ⤷ Sign Up | Pharmaceutical agents and methods relating thereto | Cushing Academy (Ashburnham, MA) | ⤷ Sign Up |
Sulopenem | ⤷ Sign Up | Compounds and their use | ALLECRA THERAPEUTICS GMBH (Lorrach, DE) | ⤷ Sign Up |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Sulopenem
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Sulopenem | Australia | AU2005244865 | 2024-05-12 | ⤷ Sign Up |
Sulopenem | Canada | CA2607686 | 2024-05-12 | ⤷ Sign Up |
Sulopenem | Canada | CA2860173 | 2024-05-12 | ⤷ Sign Up |
Sulopenem | China | CN1980694 | 2024-05-12 | ⤷ Sign Up |
Sulopenem | Denmark | DK1755661 | 2024-05-12 | ⤷ Sign Up |
Sulopenem | European Patent Office | EP1755661 | 2024-05-12 | ⤷ Sign Up |
Sulopenem | European Patent Office | EP2335722 | 2024-05-12 | ⤷ Sign Up |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |